PCP
GILD icon

Perbak Capital Partners’s Gilead Sciences GILD Stock Holding History

Perbak Capital Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$832K Buy
+5,968
New +$836K 0.2% 104
2025
Q2 		– Sell
-2,125
Closed -$238K – 299
2025
Q1 		$238K Buy
+2,125
New +$219K 0.18% 160

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Perbak Capital Partners's GILD Position: Q1 2026 in Review

Perbak Capital Partners opened a new position in Gilead Sciences (GILD) in Q1 2026: 5,968 shares worth $832K. The stake represents 0.2% of the portfolio and ranks #104 among its holdings. This is a return to the name: Perbak Capital Partners previously reported a position in GILD as recently as Q1 2025.

Perbak Capital Partners first reported a position in GILD in Q1 2025 and has held it in 2 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Perbak Capital Partners held 5,968 shares of Gilead Sciences worth $832K as of Q1 2026.
  • Gilead Sciences was a new Perbak Capital Partners position in Q1 2026.
  • Gilead Sciences made up 0.2% of Perbak Capital Partners's portfolio in Q1 2026, its #104 holding.
  • Perbak Capital Partners first reported a position in Gilead Sciences in Q1 2025 and has held it in 2 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Perbak Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.